BRPI0817889A8 - Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio - Google Patents

Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio

Info

Publication number
BRPI0817889A8
BRPI0817889A8 BRPI0817889A BRPI0817889A BRPI0817889A8 BR PI0817889 A8 BRPI0817889 A8 BR PI0817889A8 BR PI0817889 A BRPI0817889 A BR PI0817889A BR PI0817889 A BRPI0817889 A BR PI0817889A BR PI0817889 A8 BRPI0817889 A8 BR PI0817889A8
Authority
BR
Brazil
Prior art keywords
metal
mixed compound
mixed
medicine
compounds
Prior art date
Application number
BRPI0817889A
Other languages
English (en)
Inventor
Sydney Newton Maurice
John Toft Alexis
Original Assignee
Ineos Healthcare Ltd
Cytochroma Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ineos Healthcare Ltd, Cytochroma Dev Inc filed Critical Ineos Healthcare Ltd
Publication of BRPI0817889A2 publication Critical patent/BRPI0817889A2/pt
Publication of BRPI0817889A8 publication Critical patent/BRPI0817889A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F7/00—Compounds of aluminium
    • C01F7/78—Compounds containing aluminium, with or without oxygen or hydrogen, and containing two or more other elements
    • C01F7/784—Layered double hydroxide, e.g. comprising nitrate, sulfate or carbonate ions as intercalating anions
    • C01F7/785—Hydrotalcite
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/009—Compounds containing iron, with or without oxygen or hydrogen, and containing two or more other elements
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/02—Oxides; Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/20—Two-dimensional structures
    • C01P2002/22—Two-dimensional structures layered hydroxide-type, e.g. of the hydrotalcite-type
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/12—Surface area

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Geology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA, COMPOSTO MISTO DE METAL PARA USO COMO UM MEDICAMENTO, USO DE UM COMPOSTO MISTO DE METAL, E, PROCESSO PARA A PRODUÇÃO DE UM COMPOSTO MISTO DE METAL ESGOTADO DE MAGNÉSIO. A presente invenção diz respeito a compostos mistos de metal tendo atividade farmacêutica, especialmente como ligantes de fosfato. Ela também se estende aos métodos de fabricação daqueles compostos, bem como as composições farmacêuticas contendo tais compostos. Ela ainda diz respeito a seu uso farmacêutico. Em particular, a presente invenção diz respeito ao uso dos compostos de Fórmula (1): em que MII é pelo menos um metal bivalente (isto é, com duas cargas positivas); MII, é pelo menos um metal trivalente (isto é, com três cargas positivas); e 1 maior a maior 0,4.
BRPI0817889A 2007-10-16 2008-10-15 Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio BRPI0817889A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0720220.3A GB0720220D0 (en) 2007-10-16 2007-10-16 Compound
PCT/GB2008/003509 WO2009050468A1 (en) 2007-10-16 2008-10-15 Mixed metal compounds for treatment of hyperphos phataemia

Publications (2)

Publication Number Publication Date
BRPI0817889A2 BRPI0817889A2 (pt) 2015-03-31
BRPI0817889A8 true BRPI0817889A8 (pt) 2016-01-19

Family

ID=38813912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817889A BRPI0817889A8 (pt) 2007-10-16 2008-10-15 Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio

Country Status (15)

Country Link
US (1) US10155040B2 (pt)
EP (1) EP2209479B1 (pt)
JP (2) JP5622579B2 (pt)
KR (1) KR101552183B1 (pt)
CN (1) CN101827602B (pt)
AU (1) AU2008313466B2 (pt)
BR (1) BRPI0817889A8 (pt)
CA (1) CA2699576C (pt)
ES (1) ES2545388T3 (pt)
GB (1) GB0720220D0 (pt)
IL (1) IL204552A (pt)
MX (1) MX2010004089A (pt)
NZ (1) NZ583969A (pt)
WO (1) WO2009050468A1 (pt)
ZA (1) ZA201001720B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) * 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
DE102012209411A1 (de) * 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
DK3073997T3 (da) * 2013-11-27 2020-09-07 Vifor Int Ag Farmaceutisk sammensætning, omfattende phosphatbindemiddelspartikler
KR101694357B1 (ko) * 2016-05-09 2017-01-09 주식회사 후소엔지니어링 인 제거용 코팅담체의 제조방법
CN112368238A (zh) * 2018-07-12 2021-02-12 国立研究开发法人物质·材料研究机构 含有硫化氢缓释剂的包装体及其制造方法和硫化氢缓释剂、硫化氢缓释体以及使用了它们的硫化氢的产生方法
WO2020084349A1 (en) * 2018-10-25 2020-04-30 Opko Ireland Global Holdings, Ltd Methods of treatment with mixed metal compounds
CN109655418B (zh) * 2018-10-30 2022-05-13 合肥创新医药技术有限公司 一种醋酸钙片体外磷结合试验方法
CA3229571A1 (en) * 2021-08-20 2023-02-23 Duke University Layered double hydroxide particles in hydrogel matrices
CN114289159B (zh) * 2021-12-29 2023-06-06 湖北华世通生物医药科技有限公司 碳酸司维拉姆的后处理方法及其制备方法
CN119455019B (zh) * 2024-11-27 2025-10-28 北京华睿鼎信科技有限公司 碳酸镧药用组合物及其应用与治疗高磷血症的药物

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222924A (en) 1936-12-10 1940-11-26 Degussa Preparation of cerium sulphate
US2812344A (en) 1956-02-13 1957-11-05 Ortho Pharma Corp Ferrous calcium citrate complex
FR1214473A (fr) 1959-01-07 1960-04-08 Procédé de préparation d'un catalyseur à base d'hydroxyde de cérium
BE590192A (pt) 1959-04-27
US3395211A (en) 1965-12-10 1968-07-30 Carter Wallace Tableting process
US3539306A (en) 1966-07-25 1970-11-10 Kyowa Chem Ind Co Ltd Process for the preparation of hydrotalcite
US3796792A (en) 1969-12-12 1974-03-12 Kyowa Chem Ind Co Ltd Composite metal hydroxides
SU414849A1 (ru) 1971-05-21 1977-09-05 Харьковский домостроительный комбинат Бетонна смесь
BE792032A (fr) 1971-12-23 1973-03-16 Baxter Laboratories Inc Dispositif de transfert de masse ayant une membrame semi-permeable disposee en spirale et presentant un faible volume de fluide
NL174720C (nl) 1973-12-13 1984-08-01 Philips Nv Beeldweergeefcel en methode voor de vervaardiging van een vloeibaar kristallijn p-n.butyl-p'-alkoxyazobenzeen.
FR2435442A1 (fr) 1978-09-07 1980-04-04 Om Lab Sa Silicate de magnesium et d'aluminium synthetique, procede de fabrication de celui-ci et compositions pharmaceutiques comprenant celui-ci
US4192900A (en) 1978-10-12 1980-03-11 Merck & Co., Inc. Texturized starch products
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE3039997A1 (de) 1980-10-23 1982-06-03 Bayer Ag, 5090 Leverkusen Phosphonohydroxyacetonitril, ein verfahren zu seiner herstellung und seine verwendung als zwischenprodukt fuer die herstellung von arzneimitteln
US4351814A (en) 1980-12-18 1982-09-28 Kyowa Chemical Industry Co., Ltd. Hydrotalcites having a hexagonal needle-like crystal structure and process for production thereof
JPS57156419A (en) 1981-03-24 1982-09-27 Kyowa Chem Ind Co Ltd Remedy for sideropenia
US4514389A (en) 1981-05-06 1985-04-30 Kyowa Chemical Industry Co. Ltd. Gastric antacid and method for controlling pH of gastric juice
CA1198674A (en) 1981-11-23 1985-12-31 Rorer International (Holdings) Inc. Antacid compositions
US4458026A (en) 1982-06-02 1984-07-03 Union Carbide Corporation Catalysts for aldol condensations
US4582705A (en) 1982-07-12 1986-04-15 Leonard Primes Composition for detoxification
JPS606619A (ja) 1983-06-27 1985-01-14 Kyowa Chem Ind Co Ltd 鉄分欠乏症処置剤及びその製法
GB8317595D0 (en) 1983-06-29 1983-08-03 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US4609543A (en) 1983-11-14 1986-09-02 Nabisco Brands, Inc. Soft homogeneous antacid tablet
JPS60131604A (ja) 1983-12-20 1985-07-13 Victor Co Of Japan Ltd 磁気記録再生素子
DE3346943A1 (de) 1983-12-24 1985-07-04 Bayer Ag, 5090 Leverkusen Herstellung von hydrotalcit mit verbesserten eigenschaften
DE3402878A1 (de) 1984-01-27 1985-08-01 Algina AG, Zug Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen als arzneimittel
FR2559755A1 (fr) 1984-02-20 1985-08-23 Rhone Poulenc Spec Chim Oxyde cerique a nouvelles caracteristiques morphologiques et son procede d'obtention
JPS6136222A (ja) 1984-07-26 1986-02-20 Chugai Pharmaceut Co Ltd 高リン酸血症治療剤
US4566986A (en) 1984-08-31 1986-01-28 Waldmann John J Flocculating agents and processes for making them
DE3520108A1 (de) 1985-06-05 1986-12-11 Varta Batterie Ag, 3000 Hannover Positive sammlerelektrode fuer akkumulatoren mit alkalischem elektrolyten
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US4871392A (en) 1986-05-23 1989-10-03 American Cyanamid Company Aqueous suspension concentrate compositions of pendimethalin
US4801454A (en) 1986-07-17 1989-01-31 The Proctor & Gamble Company Processes for making colored pharmaceutical compositions
EP0300853B1 (fr) 1987-06-29 1991-09-18 Rhone-Poulenc Chimie Procédé d'obtention d'un oxyde cérique
US4786510A (en) 1987-07-02 1988-11-22 The Procter & Gamble Company Calcium-iron mineral supplements
US4994283A (en) 1987-07-02 1991-02-19 The Procter & Gamble Company Iron-calcium mineral supplements with enhanced bioavailability
DE3801382A1 (de) 1988-01-19 1989-08-03 Ebner Anlagen & Apparate Verfahren und anlage zur umwandlung von natriumsulfat in natriumhydroxid
EP0330284B1 (en) 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
HU201880B (en) 1988-06-21 1991-01-28 Semmelweis Orvostudomanyi Egye Process for producing pharmaceutical compositions for profilacting and treating renal diseases and for diminishing frequency of extracorporalis dialysis
GB8826333D0 (en) 1988-11-10 1988-12-14 Unilever Plc Oral compositions
US5153156A (en) 1989-04-18 1992-10-06 Aristech Chemical Corporation Process for making efficient anionic clay catalyst, catalysts made thereby, and method of making isophorone
FR2647433B1 (fr) 1989-05-23 1991-10-31 Lafarge Coppee Da Procede de preparation par voie aqueuse de sulfate de calcium purifie
US4970079A (en) 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
US5112604A (en) 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
ES2018952A6 (es) 1989-10-17 1991-05-16 Walton Sa Procedimiento de preparacion de composiciones antiacidas con tiempo prolongado de permanencia gastrica.
JP2918619B2 (ja) 1990-04-06 1999-07-12 花王株式会社 金属磁性粉末の製造方法及び磁気記録媒体用塗膜
NZ238447A (en) 1990-06-08 1993-06-25 Commw Scient Ind Res Org Metallic hydroxide anion exchange material having about 20% of its theoretical exchange capacity taken up by permanganate anions
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
DE4036757A1 (de) 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
GB2253164B (en) 1991-02-22 1994-10-05 Hoechst Uk Ltd Improvements in or relating to electrostatic coating of substrates of medicinal products
GB2254556B (en) 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
US5246899A (en) 1991-08-16 1993-09-21 Amoco Corporation Simplified preparation of hydrotalcite-type clays
JPH05155776A (ja) 1991-12-02 1993-06-22 Otsuka Pharmaceut Factory Inc 高リン血症治療剤
JPH05208816A (ja) 1992-01-28 1993-08-20 Sumitomo Metal Mining Co Ltd 水酸化セリウム及び酸化セリウムの製造方法
WO1993022237A1 (en) 1992-04-30 1993-11-11 J.M. Huber Corporation Method for production of synthetic hydrotalcite
US5380542A (en) 1992-06-19 1995-01-10 Rhone-Poulenc Specialties Chemical Co. Dietary fiber compositions for use in foods
US5273767A (en) 1992-09-09 1993-12-28 Merck & Co., Inc. Rapidly hydrating gums
WO1994009798A1 (en) 1992-10-29 1994-05-11 C-P Technology Limited Partnership Mixtures or complexes containing calcium and sulfate
NL9201907A (nl) 1992-11-02 1994-06-01 Tno Peristaltisch mengende reactor en peristaltische kleppenpomp.
DE4239442C2 (de) 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
TW397686B (en) 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
WO1995011033A1 (en) 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
MX9702006A (es) 1994-09-21 1998-04-30 Unilever Nv Composiciones orales.
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
EP0854916A4 (en) 1995-09-20 2002-07-24 Univ Queensland NEW ACC SYNTHASE GENES
US5571336A (en) 1995-09-29 1996-11-05 Wurzburger; Stephen R. Base solution for cleaning aluminum
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
EP0921726B1 (en) 1996-01-25 2004-03-31 Colin Leslie Young Stomach-action molluscicides
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE69738829D1 (de) 1996-07-12 2008-08-21 Daiichi Seiyaku Co Schnell zerfallende, druckgeformte Materialien sowie Prozess zu deren Herstellung
US5654011A (en) 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
JPH1059842A (ja) 1996-08-13 1998-03-03 Lion Corp 錠剤用組成物及び打錠方法
JPH10101569A (ja) 1996-10-01 1998-04-21 Eisai Co Ltd 制酸剤
JPH10236960A (ja) 1997-02-24 1998-09-08 Lion Corp 制酸剤含有組成物
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US6028023A (en) 1997-10-20 2000-02-22 Bulldog Technologies U.S.A., Inc. Process for making, and use of, anionic clay materials
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
JP2000086537A (ja) 1998-09-11 2000-03-28 Fuji Chem Ind Co Ltd 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US6177581B1 (en) 1999-10-12 2001-01-23 The Dow Chemical Company Mixed-metal chelates and process for the preparation thereof
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
DE19958007A1 (de) 1999-12-02 2001-06-07 Roehm Gmbh Spritzgußverfahren für (Meth)acrylat-Copolymere mit teritiären Ammoniumgruppen
EP1246629A4 (en) 2000-01-06 2007-04-18 Marantech Holding Llc METHODS USING ACTIVE ELECTRON COMPOUNDS FOR MANAGING CANCER CONDITIONS
AUPQ533700A0 (en) 2000-01-28 2000-02-17 Commonwealth Scientific And Industrial Research Organisation Soil treatment method
FR2809407B1 (fr) 2000-05-26 2002-08-30 Rhodia Chimie Sa Utilisation d'hydrotalcite comme charge dans des compositions de polymeres
US20030185886A1 (en) 2000-05-26 2003-10-02 Hanmi Pharm. Co., Ltd. Process for the preparation of rapidly disintegrating tablet
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
IN192168B (pt) 2000-11-24 2004-03-06 Council Scient Ind Res
US6576665B2 (en) 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
WO2003003809A2 (en) 2001-07-05 2003-01-16 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
UA80682C2 (en) 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
KR20080099353A (ko) 2001-08-27 2008-11-12 교와 가가꾸고교 가부시키가이샤 제산 ·완하용 정제
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
JPWO2003028706A1 (ja) 2001-09-28 2005-01-13 株式会社三和化学研究所 有核型速溶崩壊性成型品
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
US7300670B2 (en) 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
UA75831C2 (en) 2002-04-29 2006-05-15 Egyt Gyogyszervegyeszeti Gyar Process for preparation of tablets from pharmaceutically active ingredients having unfavourable tabletting properties with the use of granulating liquid containing microcrystalline cellulose
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7259192B2 (en) 2002-06-25 2007-08-21 Rhodia, Inc. Molecular weight reduction of polysaccharides by electron beams
DE60310950T2 (de) 2002-08-09 2007-11-15 Albemarle Netherlands B.V. Fischer-tropsch-verfahren unter verwendung eines eisenhaltigen schichtförmigen materiales
JP4348426B2 (ja) 2002-08-29 2009-10-21 独立行政法人産業技術総合研究所 高選択性脱リン剤及びその製造方法
WO2005012194A1 (en) 2003-01-28 2005-02-10 The University Of Wyoming Research Corporation D/B/A Western Research Institute Charge-based water filtration systems
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EP1660104B1 (en) 2003-08-26 2010-03-10 Shire Holdings AG Pharmaceutical formulation comprising lanthanum compounds
WO2005027876A1 (en) 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
US20050260271A1 (en) 2004-05-20 2005-11-24 Eastman Kodak Company Composition comprising layered host material with intercalated functional-active organic compound
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060177415A1 (en) 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
JP4823547B2 (ja) 2005-03-28 2011-11-24 株式会社ジーシー ペースト状歯科用アルギン酸塩印象材組成物
RU2496480C2 (ru) 2005-12-28 2013-10-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат с контролируемым высвобождением
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
EP2034958B1 (en) 2006-05-19 2009-10-28 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
EP1932808A1 (en) 2006-12-14 2008-06-18 Novartis AG Iron(III)-Carbohydrate based phosphate adsorbent
PT2319804E (pt) 2006-12-14 2014-11-24 Novartis Ag Adsorvente de fosfato à base de ferro (iii)-carboidrato
EP1946750A1 (en) 2007-01-18 2008-07-23 The Jordanian Pharmaceutical Manufacturing Co. Co-precipitate, method for preparing the same and uses thereof
WO2008129034A1 (en) 2007-04-20 2008-10-30 Euro Support Catalyst Group Bv Hydrotalcite-like layered double hydroxide (ldh) composition and process of making same
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Also Published As

Publication number Publication date
CA2699576C (en) 2018-06-26
EP2209479A1 (en) 2010-07-28
US20100215770A1 (en) 2010-08-26
GB0720220D0 (en) 2007-11-28
AU2008313466A1 (en) 2009-04-23
JP2011500654A (ja) 2011-01-06
MX2010004089A (es) 2010-04-30
KR101552183B1 (ko) 2015-09-10
JP5622579B2 (ja) 2014-11-12
HK1142525A1 (zh) 2010-12-10
CN101827602A (zh) 2010-09-08
AU2008313466B2 (en) 2014-10-23
ES2545388T3 (es) 2015-09-10
ZA201001720B (en) 2011-05-25
JP2014101390A (ja) 2014-06-05
NZ583969A (en) 2012-05-25
IL204552A (en) 2016-12-29
CN101827602B (zh) 2013-10-30
KR20100057078A (ko) 2010-05-28
IL204552A0 (en) 2010-11-30
WO2009050468A1 (en) 2009-04-23
CA2699576A1 (en) 2009-04-23
BRPI0817889A2 (pt) 2015-03-31
US10155040B2 (en) 2018-12-18
EP2209479B1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
BRPI0817889A8 (pt) Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0717773A2 (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BRPI0717970C1 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
ECSP088875A (es) Tienopirimidinas con actividad inhibidora de mnk1/mnk2 para composiciones farmacéuticas
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
BRPI0510412A (pt) compostos orgánicos
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
MX2009003823A (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas.
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
BRPI0507034A (pt) compostos orgánicos
BRPI0514137A (pt) uso de pelo menos um composto heterocìclico, composição de combustìvel, concentrado de aditivos, e, processo para preparar uma composição de combustìvel
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CYTOCHROMA DEVELOPMENT INC. (BB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements